Cancer gene therapy is the transfer of genetic material to the cells of an individual with the goal of eradicating cancer cells, both in the primary tumor and metastases. Cancer gene therapy strategies exploit our expanding knowledge of the genetic basis of cancer, thereby allowing rationally targeted interventions at the molecular level. The successful implementation of cancer gene therapy in the clinic awaits the development of vectors capable of specific and efficient gene delivery to cancer cells. The first clinical applications of cancer gene therapy are likely to be in combination with conventional therapies, such as radiotherapy and immunotherapy.
SeemayerT. A., CaveneeW. K.Molecular Mechanisms of Oncogenesis. Lab. Invest.60, 585–599 (1989).
2.
RothJ. A., SwisherS. G., MeynR. E.p53 Tumor Suppressor Gene Therapy for Cancer. Oncology13, 148–154 (1999).
3.
NikitinA. Y., RileyD. J., LeeW. H.A Paradigm for Cancer Treatment Using the Retinoblastoma Gene in a Mouse Model. Ann. N. Y. Acad. Sci.886, 12–22 (1999).
4.
CheneyI. W., JohnsonD. E., VaillancourtM. T., AvanziniJ., MorimotoA., DemersG. W., WillsK. N., ShabramP. W., BolenJ. B., TavtigianS. V., BooksteinR.Suppression of Tumorigenicity of Glioblastoma Cells by Adenovirus-mediated MMAC1/PTEN Gene Transfer. Cancer Res.58, 2331–2334 (1998).
5.
GrimJ., D'AmicoA., FrizelleS., ZhouJ., KratzkeR. A., CurielD. T.Adenovirus-mediated Delivery of p16 to p16-deficient Human Bladder Cancer Cells Confers Chemoresistance to Cisplatin and Paclitaxel. Clin. Cancer Res.3, 2415–2423 (1997).
6.
MerrittJ. A., RothJ. A., LogothetisC. J.Clinical Evaluation of Adenoviral-mediated p53 Gene Transfer: Review of INGN 201 Studies. Semin. Oncol.28, 105–114 (2001).
7.
DameronK. M., VolpertO. V., TainskyM. A., BouckN.The p53 Tumor Suppressor Gene Inhibits Angiogenesis by Stimulating the Production of Thrombospondin. Cold Spring Harb. Symp. Quant. Biol.59, 483–489 (1994).
8.
BouvetM., EllisL. M., NishizakiM., FujiwaraT., LiuW., BucanaC. D., FangB., LeeJ. J., RothJ. A.Adenovirus-mediated Wild-type p53 Gene Transfer Down-regulates Vascular Endothelial Growth Factor Expression and Inhibits Angiogenesis in Human Colon Cancer. Cancer Res.58, 2288–2292 (1998).
9.
NishizakiM., FujiwaraT., TanidaT., HizutaA., NishimoriH., TokinoT., NakamuraY., BouvetM., RothJ. A., TanakaN.Recombinant Adenovirus Expressing Wild-type p53 is Antiangiogenic: A Proposed Mechanism for Bystander Effect. Clin. Cancer Res.5, 1015–1023 (1999).
10.
RothJ. A., GrammerS. F., SwisherS. G., KomakiR., NemunaitisJ., MerrittJ., MeynR. E.P53 Gene Replacement for Cancer-interactions with DNA Damaging Agents. Acta Oncol.40, 739–744 (2001).
WangH., PrasadG., BuolamwiniJ. K., ZhangR.Antisense Anticancer Oligonucleotide Therapeutics. Curr. Cancer Drug Targets1, 177–196 (2001).
13.
ShiX. B., GumerlockP. H., MuenzerJ. T., deVere WhiteR. W.BCL2 Antisense Transcripts Decrease Intracellular Bcl2 Expression and Sensitize LNCaP Prostate Cancer Cells to Apoptosis-inducing Agents. Cancer Biother. Radiopharm.16, 421–429 (2001).
14.
de FabritiisP., PettiM. C., MontefuscoE., De ProprisM. S., SalaR., BellucciR., ManciniM., LisciA., BonettoF., GeiserT., CalabrettaB., MandelliF.BCR-ABL Antisense Oligodeoxy-nucleotide in vitro Purging and Autologous Bone Marrow Transplantation for Patients with Chronic Myelogenous Leukemia in Advanced Phase. Blood91, 3156–3162 (1998).
15.
KasidU., PfeiferA., BrennanT., BeckettM., WeichselbaumR. R., DritschiloA., MarkG. E.Effect of Antisense c-raf-1 on Tumorigenicity and Radiation Sensitivity of a Human Squamous Carcinoma. Science243, 1354–1356 (1989).
16.
WatsonP. H., PonR. T., ShiuR. P.Inhibition of c-myc Expression by Phosphorothioate Antisense Oligonucleotide Identifies a Critical Role for c-myc in the Growth of Human Breast Cancer. Cancer Res.51, 3996–4000 (1991).
17.
WangH., NanL., YuD., AgrawalS., ZhangR.Antisense Anti-MDM2 Oligonucleotides as a Novel Therapeutic Approach to Human Breast Cancer: in vitro and in vivo Activities and Mechanisms. Clin. Cancer Res.7, 3613–3624 (2001).
18.
HaseloffJ., GerlachW. L.Simple RNA Enzymes with New and Highly Specific Endoribonuclease Activities. Nature334, 585–591 (1988).
19.
HerskowitzI.Functional Inactivation of Genes by Dominant Negative Mutations. Nature329, 219–222 (1987).
20.
KashlesO., YardenY., FischerR., UllrichA., SchlessingerJ.A Dominant Negative Mutation Suppresses the Function of Normal Epidermal Growth Factor Receptors by Heterodimerization. Mol. Cell Biol.11, 1454–1463 (1991).
21.
UenoH., ColbertH., EscobedoJ. A., WilliamsL. T.Inhibition of PDGF Beta Receptor Signal Transduction by Coexpression of a Truncated Receptor. Science252, 844–848 (1991).
22.
LopezA. R., CookJ., DeiningerP. L., DerynckR.Dominant Negative Mutants of Transforming Growth Factor-beta 1 Inhibit the Secretion of Different Transforming Growth Factor-beta Isoforms. Mol. Cell Biol.12, 1674–1679 (1992).
23.
ShamahS. M., StilesC. D., GuhaA.Dominant-negative Mutants of Platelet-derived Growth Factor Revert the Transformed Phenotype of Human Astrocytoma Cells. Mol. Cell Biol.13, 7203–7212 (1993).
24.
PragerD., LiH. L., AsaS., MelmedS.Dominant Negative Inhibition of Tumorigenesis in vivo by Human Insulin-like Growth Factor I Receptor Mutant. Proc. Natl Acad. Sci. USA91, 2181–2185 (1994).
25.
PouliotF., BlaisA., LabrieC.Overexpression of a Dominant Negative Type II Bone Morphogenetic Protein Receptor Inhibits the Growth of Human Breast Cancer Cells. Cancer Res.63, 277–281 (2003).
26.
DeshaneJ., LoechelF., ConryR. M., SiegalG. P., KingC. R., CurielD. T.Intracellular Single-chain Antibody Directed Against erbB2 Down-regulates Cell Surface erbB2 and Exhibits a Selective Anti-proliferative Effect in erbB2 Overexpressing Cancer Cell Lines. Gene Ther.1, 332–337 (1994).
27.
DeshaneJ., CabreraG., GrimJ. E., SiegalG. P., PikeJ., AlvarezR. D., CurielD. T.Targeted Eradication of Ovarian Cancer Mediated by Intracellular Expression of Anti-erbB-2 Single-chain Antibody. Gynecol. Oncol.59, 8–14 (1995).
28.
ArafatW. O., Gomez-NavarroJ., BuchsbaumD. J., XiangJ., WangM., CasadoE., BarkerS. D., MahasreshtiP. J., HaismaH. J., BarnesM. N., SiegalG. P., AlvarezR. D., HemminkiA., NettelbeckD. M., CurielD. T.Effective Single Chain Antibody (scFv) Concentrations in vivo via Adenoviral Vector Mediated Expression of Secretory scFv. Gene Ther.9, 256–262 (2002).
29.
MooltenF. L., WellsJ. M.Curability of Tumors Bearing Herpes Thymidine Kinase Genes Transferred by Retroviral Vectors. J. Natl Cancer Inst.82, 297–300 (1990).
30.
DilberM. S., AbediM. R., ChristenssonB., BjorkstrandB., KidderG. M., NausC. C., GahrtonG., SmithC. I.Gap Junctions Promote the Bystander Effect of Herpes Simplex Virus Thymidine Kinase in vivo. Cancer Res.57, 1523–1528 (1997).
31.
BlackburnR. V., GaloforoS. S., CorryP. M., LeeY. J.Adenoviral-mediated Transfer of a Heat-inducible Double Suicide Gene into Prostate Carcinoma Cells. Cancer Res.58, 1358–1362 (1998).
32.
RogulskiK. R., KimJ. H., KimS. H., FreytagS. O.Glioma Cells Transduced with an Escherichia Coli CD/HSV-1 TK Fusion Gene Exhibit Enhanced Metabolic Suicide and Radiosensitivity. Hum. Gene Ther.8, 73–85 (1997).
33.
AghiM., KrammC. M., ChouT. C., BreakefieldX. O., ChioccaE. A.Synergistic Anticancer Effects of Ganciclovir/thymidine Kinase and 5-fluorocytosine/cytosine Deaminase Gene Therapies. J. Natl Cancer Inst.90, 370–380 (1998).
34.
PedersonL. C., BuchsbaumD. J., VickersS. M., KancharlaS. R., MayoM. S., CurielD. T., StackhouseM. A.Molecular Chemotherapy Combined with Radiation Therapy Enhances Killing of Cholangiocarcinoma Cells in vitro and in vivo. Cancer Res.57, 4325–4332 (1997).
35.
CulverK. W., RamZ., WallbridgeS., IshiiH., OldfieldE. H., BlaeseR. M.In vivo Gene Transfer with Retroviral Vector-producer Cells for Treatment of Experimental Brain Tumors. Science256, 1550–1552 (1992).
36.
AdachiY., ReynoldsP. N., YamamotoM., GrizzleW. E., OverturfK., MatsubaraS., MuramatsuT., CurielD. T.Midkine Promoter-based Adenoviral Vector Gene Delivery for Pediatric Solid Tumors. Cancer Res.60, 4305–4310 (2000).
YamamotoM., AlemanyR., AdachiY., GrizzleW. E., CurielD. T.Characterization of the Cyclooxygenase-2 Promoter in an Adenoviral Vector and its Application for the Mitigation of Toxicity in Suicide Gene Therapy of Gastrointestinal Cancers. Mol. Ther.3, 385–394 (2001). Emiliusen, L., Gough, M., Bateman, A., Ahmed, A., Voellmy, R.,.
39.
ChesterJ., DiazR. M., HarringtonK., VileR.A Transcriptional Feedback Loop for Tissue-specific Expression of Highly Cytotoxic Genes which Incorporates an Immunostimulatory Component. Gene Ther.8, 987–998 (2001).
40.
KochP. E., GuoZ. S., KagawaS., GuJ., RothJ. A., FangB.Augmenting Transgene Expression from Carcinoembryonic Antigen (CEA) Promoter via a GAL4 Gene Regulatory System. Mol. Ther.3, 278–283 (2001).
41.
SouthamC. M., MooreA. E.Clinical Studies of Viruses as Antineoplastic Agents, with Particular Reference to Egypt 101 Virus. Cancer5, 1025–1034 (1952).
42.
SmithR. R., HuebnerR. J., RoweW. P., SchattenW. E., SchattenB., SchattenT. L.Studies on the use of Viruses in the Treatment of Carcinoma of the Cervix. Cancer9, 1211–1218 (1956).
43.
StojdlD. F., LichtyB., KnowlesS., MariusR., AtkinsH., SonenbergN., BellJ. C.Exploiting Tumor-specific Defects in the Interferon Pathway with a Previously Unknown Oncolytic Virus. Nat. Med.6, 821–825 (2000).
44.
CoffeyM. C., StrongJ. E., ForsythP. A., LeeP. W.Reovirus Therapy of Tumors with Activated Ras Pathway. Science282, 1332–1334 (1998).
45.
WilcoxM. E., YangW., SengerD., RewcastleN. B., MorrisD. G., BrasherP. M., ShiZ. Q., JohnstonR. N., NishikawaS., LeeP. W., ForsythP. A.Reovirus as an Oncolytic Agent Against Experimental Human Malignant Gliomas. J. Natl Cancer Inst.93, 903–912 (2001).
HirasawaK., NishikawaS. G., NormanK. L., AlainT., KossakowskaA., LeeP. W.Oncolytic Reovirus Against Ovarian and Colon Cancer. Cancer Res.62, 1696–1701 (2002).
48.
NormanK. L., CoffeyM. C., HirasawaK., DemetrickD. J., NishikawaS. G., DiFrancescoL. M., StrongJ. E., LeeP. W.Reovirus Oncolysis of Human Breast Cancer. Hum. Gene Ther.13, 641–652 (2002).
49.
GroteD., RussellS. J., CornuT. I., CattaneoR., VileR., PolandG. A., FieldingA. K.Live Attenuated Measles Virus Induces Regression of Human Lymphoma Xenografts in Immunodeficient Mice. Blood97, 3746–3754 (2001).
50.
PengK. W., AhmannG. J., PhamL., GreippP. R., CattaneoR., RussellS. J.Systemic Therapy of Myeloma Xenografts by an Attenuated Measles Virus. Blood98, 2002–2007 (2001).
51.
PengK. W., TenEyckC. J., GalanisE., KalliK. R., HartmannL. C., RussellS. J.Intraperitoneal Therapy of Ovarian Cancer using an Engineered Measles Virus. Cancer Res.62, 4656–4662 (2002).
52.
VargheseS., RabkinS. D.Oncolytic Herpes Simplex Virus Vectors for Cancer Virotherapy. Cancer Gene Ther.9, 967–968 (2002).
53.
MinetaT., RabkinS. D., YazakiT., HunterW. D., MartuzaR. L.Attenuated Multi-mutated Herpes Simplex Virus-1 for the Treatment of Malignant Gliomas. Nat. Med.1, 938–943 (1995).
54.
MarkertJ. M., MedlockM. D., RabkinS. D., GillespieG. Y., TodoT., HunterW. D., PalmerC. A., FeigenbaumF., TornatoreC., TufaroF., MartuzaR. L.Conditionally Replicating Herpes Simplex Virus Mutant, G207 for the treatment of Malignant Glioma: Results of a Phase I Trial. Gene Ther.7, 867–874 (2000).
55.
TodoT., MartuzaR. L., RabkinS. D., JohnsonP. A.Oncolytic Herpes Simplex Virus Vector with Enhanced MHC Class I Presentation and Tumor Cell Killing. Proc. Natl Acad. Sci. USA98, 6396–6401 (2001).
56.
AghiM., ChouT. C., SulingK., BreakefieldX. O., ChioccaE. A.Multimodal Cancer Treatment Mediated by a Replicating Oncolytic Virus that Delivers the Oxazaphosphorine/rat Cytochrome P450 2B1 and Ganciclovir/herpes Simplex Virus Thymidine Kinase Gene Therapies. Cancer Res.59, 3861–3865 (1999).
57.
ParkerJ. N., GillespieG. Y., LoveC. E., RandallS., WhitleyR. J., MarkertJ. M.Engineered Herpes Simplex Virus Expressing IL-12 in the Treatment of Experimental Murine Brain Tumors. Proc. Natl Acad. Sci. USA97, 2208–2213 (2000).
58.
AlemanyR., BalagueC., CurielD. T.Replicative adenoviruses for cancer therapy. Nat. Biotechnol.18, 723–727 (2000).
59.
BischoffJ. R., KirnD. H., WilliamsA., HeiseC., HornS., MunaM., NgL., NyeJ. A., Sampson-JohannesA., FattaeyA., McCormickF.An Adenovirus Mutant that Replicates Selectively in p53-deficient Human Tumor Cells. Science274, 373–376 (1996).
60.
KirnD., HermistonT., McCormickF.ONYX-015: Clinical Data are Encouraging. Nat. Med.4, 1341–1342 (1998).
61.
GanlyI., KirnD., EckhardtG., RodriguezG. I., SoutarD. S., OttoR., RobertsonA. G., ParkO., GulleyM. L., HeiseC., Von HoffD. D., KayeS. B., EckhardtS. G.A Phase I Study of Onyx-015, An E1B Attenuated Adenovirus, Administered Intratumorally to Patients with Recurrent Head and Neck Cancer. Clin. Cancer Res.6, 798–806 (2000).
62.
KhuriF. R., NemunaitisJ., GanlyI., ArseneauJ., TannockI. F., RomelL., GoreM., IronsideJ., MacDougallR. H., HeiseC., RandlevB., GillenwaterA. M., BrusoP., KayeS. B., HongW. K., KirnD. H.A Controlled Trial of Intratumoral ONYX-015, A Selectively-replicating Adenovirus, in Combination with Cisplatin and 5-fluorouracil in Patients with Recurrent Head and Neck Cancer. Nat. Med.6, 879–885 (2000).
63.
FueyoJ., Gomez-ManzanoC., AlemanyR., LeeP. S., McDonnellT. J., MitliangaP., ShiY. X., LevinV. A., YungW. K., KyritsisA. P.A Mutant Oncolytic Adenovirus Targeting the Rb Pathway Produces Anti-glioma Effect in vivo.Oncogene19, 2–12 (2000).
BauerschmitzG. J., LamJ. T., KanervaA., SuzukiK., NettelbeckD. M., DmitrievI., KrasnykhV., MikheevaG. V., BarnesM. N., AlvarezR. D., DallP., AlemanyR., CurielD. T., HemminkiA.Treatment of Ovarian Cancer with a Tropism Modified Oncolytic Adenovirus. Cancer Res.62, 1266–1270 (2002).
66.
AdachiY., ReynoldsP. N., YamamotoM., WangM., TakayamaK., MatsubaraS., MuramatsuT., CurielD. T.AMidkine Promoter-based Conditionally Replicative Adenovirus for Treatment of Pediatric Solid Tumors and Bone Marrow Tumor Purging. Cancer Res.61, 7882–7888 (2001).
67.
TakahashiM., SatoT., SagawaT., LuY., SatoY., IyamaS., YamadaY., FukauraJ., TakahashiS., MiyanishiK., YamashitaT., SasakiK., KogawaK., HamadaH., KatoJ., NiitsuY.E1B-55K-Deleted Adenovirus Expressing E1A-13S by AFP-enhancer/promoter is Capable of Highly Specific Replication in AFP-producing Hepatocellular Carcinoma and Eradication of Established Tumor. Mol. Ther.5, 627–634 (2002).
68.
RodriguezR., SchuurE. R., LimH. Y., HendersonG. A., SimonsJ. W., HendersonD. R.Prostate Attenuated Replication Competent Adenovirus (ARCA) CN706: A Selective Cytotoxic for Prostate-specific Antigen-positive Prostate Cancer Cells. Cancer Res.57, 2559–2563 (1997).
69.
YuD. C., ChenY., SengM., DilleyJ., HendersonD. R.The Addition of Adenovirus Type 5 Region E3 Enables Calydon Virus 787 to Eliminate Distant Prostate Tumor Xenografts. Cancer Res.59, 4200–4203 (1999).
70.
HavivY. S., TakayamaK., GlasgowJ. N., BlackwellJ. L., WangM., LeiX., CurielD. T.A Model System for the Design of Armed Replicating Adenoviruses Using p53 as a Candidate Transgene. Mol. Cancer Ther.1, 321–328 (2002).
71.
FreytagS. O., RogulskiK. R., PaielliD. L., GilbertJ. D., KimJ. H.A Novel Three-pronged Approach to Kill Cancer Cells Selectively: Concomitant Viral, Double Suicide Gene, and Radiotherapy. Hum. Gene Ther.9, 1323–1333 (1998).
72.
WildnerO., BlaeseR. M., MorrisJ. C.Therapy of Colon Cancer is Enhanced by the Addition of Herpes Simplex Virus Thymidine Kinase. Cancer Res.59, 410–413 (1999).
73.
WildnerO., MorrisJ. C., VahanianN. N., FordH.Jr., RamseyW. J., BlaeseR. M.Adenoviral Vectors Capable of Replication Improve the Efficacy of HSVtk/GCV Suicide Gene Therapy of Cancer. Gene Ther.6, 57–62 (1999).
74.
FolkmanJ.Anti-angiogenesis: New Concept for Therapy of Solid Tumors. Ann. Surg.175, 409–416 (1972).
75.
BoehmT., FolkmanJ., BrowderT., O'ReillyM. S.Antiangiogenic Therapy of Experimental Cancer does not Induce Acquired Drug Resistance. Nature390, 404–407 (1997).
76.
GoldmanC. K., KendallR. L., CabreraG., SoroceanuL., HeikeY., GillespieG. Y., SiegalG. P., MaoX., BettA. J., HuckleW. R., ThomasK. A., CurielD. T.Paracrine Expression of a Native Soluble Vascular Endothelial Growth Factor Receptor Inhibits Tumor Growth, Metastasis, and Mortality Rate. Proc. Natl Acad. Sci. USA95, 8795–8800 (1998).
77.
OgawaT., TakayamaK., TakakuraN., KitanoS., UenoH.Anti-tumor Angiogenesis Therapy Using Soluble Receptors: Enhanced Inhibition of Tumor Growth When Soluble Fibroblast Growth Factor Receptor-1 is used with Soluble Vascular Endothelial Growth Factor Receptor. Cancer Gene Ther.9, 633–640 (2002).
78.
O'ReillyM. S., HolmgrenL., ShingY., ChenC., RosenthalR. A., MosesM., LaneW. S., CaoY., SageE. H., FolkmanJ.Angiostatin: A Novel Angiogenesis Inhibitor that Mediates the Suppression of Metastases by a Lewis Lung Carcinoma. Cell79, 315–328 (1994).
79.
O'ReillyM. S., BoehmT., ShingY., FukaiN., VasiosG., LaneW. S., FlynnE., BirkheadJ. R., OlsenB. R., FolkmanJ.Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth. Cell88, 277–285 (1997).
80.
DavidoffA. M., NathwaniA. C., SpurbeckW. W., NgC. Y., ZhouJ., VaninE. F.rAAV-mediated Long-term Liver-generated Expression of an Angiogenesis Inhibitor can Restrict Renal Tumor Growth in Mice. Cancer Res.62, 3077–3083 (2002).
81.
BrandK., BakerA. H., Perez-CantoA., PosslingA., SacharjatM., GeheebM., ArnoldW.Treatment of Colorectal Liver Metastases by Adenoviral Transfer of Tissue Inhibitor of Metalloproteinases-2 into the Liver Tissue. Cancer Res.60, 5723–5730 (2000).
82.
LiH., LindenmeyerF., GrenetC., OpolonP., MenashiS., SoriaC., YehP., PerricaudetM., LuH.AdTIMP-2 Inhibits Tumor Growth, Angiogenesis, and Metastasis, and Prolongs Survival in Mice. Hum. Gene Ther.12, 515–526 (2001).
83.
SpurbeckW. W., NgC. Y., StromT. S., VaninE. F., DavidoffA. M.Enforced Expression of Tissue Inhibitor of Matrix Metalloproteinase-3 Affects Functional Capillary Morphogenesis and Inhibits Tumor Growth in a Murine Tumor Model. Blood100, 3361–3368 (2002).
84.
CurielD. T., DouglasJ. T.Vector Targeting for Therapeutic Gene Delivery. pp. 728. New York, Wiley, 2002.
85.
MillerC. R., BuchsbaumD. J., ReynoldsP. N., DouglasJ. T., GillespieG. Y., MayoM. S., RabenD., CurielD. T.Differential Susceptibility of Primary and Established Human Glioma Cells to Adenovirus Infection: Targeting via the Epidermal Growth Factor Receptor Achieves Fiber Receptor-independent Gene Transfer. Cancer Res.58, 5738–5748 (1998).
86.
DouglasJ. T., KimM., SumerelL. A., CareyD. E., CurielD. T.Efficient Oncolysis by a Replicating Adenovirus (Ad) in vivo is Critically Dependent on Tumor Expression of Primary Ad Receptors. Cancer Res.61, 813–817 (2001).
87.
KimM., ZinnK. R., BarnettB. G., SumerelL. A., KrasnykhV., CurielD. T., DouglasJ. T.The Therapeutic Efficacy of Adenoviral Vectors for Cancer Gene Therapy is Limited by a Low Level of Primary Adenovirus Receptors on Tumour Cells. Eur. J. Cancer38, 1917–1926 (2002).
KanervaA., MikheevaG. V., KrasnykhV., CoolidgeC. J., LamJ. T., MahasreshtiP. J., BarkerS. D., StraughnM., BarnesM. N., AlvarezR. D., HemminkiA., CurielD. T.Targeting Adenovirus to the Serotype 3 Receptor Increases Gene Transfer Efficiency to Ovarian Cancer Cells. Clin. Cancer Res.8, 275–280 (2002).
90.
DmitrievI., KrasnykhV., MillerC. R., WangM., KashentsevaE., MikheevaG., BelousovaN., CurielD. T.An Adenovirus Vector with Genetically Modified Fibers Demonstrates Expanded Tropism via Utilization of a Coxsackievirus and Adenovirus Receptor-independent Cell Entry Mechanism. J. Virol.72, 9706–9713 (1998).
91.
VanderkwaakT. J., WangM., Gomez-NavarroJ., RancourtC., DmitrievI., KrasnykhV., BarnesM., SiegalG. P., AlvarezR., CurielD. T.An Advanced Generation of Adenoviral Vectors Selectively Enhances Gene Transfer for Ovarian Cancer Gene Therapy Approaches. Gynecol. Oncol.74, 227–234 (1999).
92.
HemminkiA., ZinnK. R., LiuB., ChaudhuriT. R., DesmondR. A., RogersB. E., BarnesM. N., AlvarezR. D., CurielD. T.In vivo Molecular Chemotherapy and Noninvasive Imaging with an Infectivity-enhanced Adenovirus. J. Natl Cancer Inst.94, 741–749 (2002).
93.
SnitkovskyS., YoungJ. A.Cell-specific Viral Targeting Mediated by a Soluble Retroviral Receptor-ligand Fusion Protein. Proc. Natl Acad. Sci. USA.95, 7063–7068 (1998).
94.
KasaharaN., DozyA. M., KanY. W.Tissue-specific Targeting of Retroviral Vectors Through Ligand-receptor Interactions. Science266, 1373–1376 (1994).
95.
HallF. L., LiuL., ZhuN. L., StapferM., AndersonW. F., BeartR. W., GordonE. M.Molecular Engineering of Matrix-targeted Retroviral vectors Incorporating a Surveillance Function Inherent in von Willebrand Factor. Hum. Gene Ther.11, 983–993 (2000).
96.
NilsonB. H., MorlingF. J., CossetF. L., RussellS. J.Targeting of Retroviral Vectors Through Protease-substrate Interactions. Gene Ther.3, 280–286 (1996).
97.
BarnettB. G., TillmanB. W., CurielD. T., DouglasJ. T.Dual Targeting of Adenoviral Vectors at the Levels of Transduction and Transcription Enhances the Specificity of Gene Expression in Cancer Cells. Mol. Ther.6, 377–385 (2002).
98.
DanksM. K., MortonC. L., PawlikC. A., PotterP. M.Overexpression of a Rabbit Liver Carboxylesterase Sensitizes Human Tumor Cells to CPT-11. Cancer Res.58, 20–22 (1998).
99.
MeckM. M., WierdlM., WagnerL. M., BurgerR. A., GuichardS. M., KrullE. J., HarrisL. C., PotterP. M., DanksM. K.AVirus-directed Enzyme Prodrug Therapy Approach to Purging Neuroblastoma Cells from Hematopoietic Cells using Adenovirus Encoding Rabbit Carboxylesterase and CPT-11. Cancer Res.61, 5083–5089 (2001).
100.
WagnerL. M., GuichardS. M., BurgerR. A., MortonC. L., StraignC. M., AshmunR. A., HarrisL. C., HoughtonP. J., PotterP. M., DanksM. K.Efficacy and Toxicity of a Virus-directed Enzyme Prodrug Therapy Purging Method: Preclinical Assessment and Application to Bone Marrow Samples from Neuroblastoma Patients. Cancer Res.62, 5001–5007 (2002).
101.
MaraisR., SpoonerR. A., StribblingS. M., LightY., MartinJ., SpringerC. J.A Cell Surface Tethered Enzyme Improves Efficiency in Gene-directed Enzyme Prodrug Therapy. Nat. Biotechnol.15, 1373–1377 (1997).
102.
FriedlosF., DaviesL., ScanlonI., OgilvieL. M., MartinJ., StribblingS. M., SpoonerR. A., Niculescu-DuvazI., MaraisR., SpringerC. J.Three New Prodrugs for Suicide Gene Therapy Using Carboxypeptidase G2 Elicit Bystander Efficacy in Two Xenograft Models. Cancer Res.62, 1724–1729 (2002).
103.
HirschowitzE. A., OhwadaA., PascalW. R., RussiT. J., CrystalR. G.In vivo Adenovirus-mediated Gene Transfer of the Escherichia Coli Cytosine Deaminase Gene to Human Colon Carcinoma-derived Tumors Induces Chemosensitivity to 5-fluorocytosine. Hum. Gene Ther.6, 1055–1063 (1995).
104.
LawrenceT. S., RehemtullaA., NgE. Y., WilsonM., TroskoJ. E., StetsonP. L.Preferential Cytotoxicity of Cells Transduced with Cytosine Deaminase Compared to Bystander Cells after Treatment with 5-flucytosine. Cancer Res.58, 2588–2593 (1998).
105.
TopfN., WorgallS., HackettN. R., CrystalR. G.Regional ‘Prodrug’ Gene Therapy: Intravenous Administration of an Adenoviral Vector Expressing the E. Coli Cytosine Deaminase Gene and Systemic Administration of 5-fluorocytosine Suppresses Growth of Hepatic Metastasis of Colon Carcinoma. Gene Ther.5, 507–513 (1998).
106.
JounaidiY., WaxmanD. J.Combination of the Bioreductive Drug Tirapazamine with the Chemotherapeutic Prodrug Cyclophosphamide for P450/P450-reductase-based Cancer Gene Therapy. Cancer Res.60, 3761–3769 (2000).
107.
JounaidiY., WaxmanD. J.Frequent, Moderate-dose Cyclophosphamide Administration Improves the Efficacy of Cytochrome P-450/cytochrome P-450 Reductase-based Cancer Gene Therapy. Cancer Res.61, 4437–4444 (2001).
108.
SchwartzP. S., ChenC. S., WaxmanD. J.Enhanced Bystander Cytotoxicity of P450 Gene-directed Enzyme Prodrug Therapy by Expression of the Antiapoptotic Factor p35. Cancer Res.62, 6928–6937 (2002).
109.
VileR. G., HartI. R.Use of Tissue-specific Expression of the Herpes Simplex Virus Thymidine Kinase Gene to Inhibit Growth of Established Murine Melanomas Following Direct Intratumoral Injection of DNA. Cancer Res.53, 3860–3864 (1993).
110.
BridgewaterJ. A., SpringerC. J., KnoxR. J., MintonN. P., MichaelN. P., CollinsM. K.Expression of the Bacterial Nitroreductase Enzyme in Mammalian Cells Renders them Selectively Sensitive to Killing by the Prodrug CB1954. Eur. J. Cancer31A, 2362–70 (1995).
111.
DjehaA. H., ThomsonT. A., LeungH., SearleP. F., YoungL. S., KerrD. J., HarrisP. A., MountainA., WrightonC. J.Combined Adenovirus-mediated Nitroreductase Gene Delivery and CB1954 Treatment: A Well-tolerated Therapy for Established Solid Tumors. Mol. Ther.3, 233–240 (2001).
112.
WilsonW. R., PullenS. M., HoggA., HelsbyN. A., HicksK. O., DennyW. A.Quantitation of Bystander Effects in Nitroreductase Suicide Gene Therapy Using Three-dimensional Cell Cultures. Cancer Res.62, 1425–1432 (2002).
113.
ParkerW. B., KingS. A., AllanP. W., BennettL. L.Jr., SecristJ. A.3rd, MontgomeryJ. A., GilbertK. S., WaudW. R., WellsA. H., GillespieG. Y., SorscherE. J.In vivo Gene Therapy of Cancer with E. Coli Purine Nucleoside Phosphorylase. Hum. Gene Ther.8, 1637–1644 (1997).
114.
HughesB. W., KingS. A., AllanP. W., ParkerW. B., SorscherE. J.Cell to Cell Contact is not Required for Bystander Cell Killing by Escherichia Coli Purine Nucleoside Phosphorylase. J. Biol. Chem.273, 2322–2328 (1998).
115.
GadiV. K., AlexanderS. D., KudlowJ. E., AllanP., ParkerW. B., SorscherE. J.In vivo Sensitization of Ovarian Tumors to Chemotherapy by Expression of E. Coli Purine Nucleoside Phosphorylase in a Small Fraction of Cells. Gene Ther.7, 1738–1743 (2000).
116.
WeyelD., SedlacekH. H., MullerR., BrusselbachS.Secreted Human Beta-glucuronidase: A Novel Tool for Gene-directed Enzyme Prodrug Therapy. Gene Ther.7, 224–231 (2000).
